Expert Interview
Evaluating Alnylam Pharmaceuticals' Zilebesiran (ALN-AGT) for Hypertension
Ticker(s): ALNYInstitution: Renown Medical Center Institute for Heart and Vascular Health (Nevada)
- Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Medical Center Institute for Heart and Vascular Health; served as Vice President of the Board of the American Society of Hypertension (ASH).
- Manages hundreds of patients with hypertension, about ~40 patients with lp(a) >150 mg/dl, and <150 patients with SHTG
- Clinical Interests include management of hypertension, dyslipidemia, anticoagulation, vascular disease, and heart disease and stroke prevention.
- Principal investigator on numerous clinical trials, most recently focused in the field of device therapy for hypertension. Research focused on diagnosis and management of renovascular disease and exploring novel means of overcoming barriers to hypertension and dyslipidemia control.
How does the mechanism of action for Zilebesiran (ALN-AGT) differentiate itself from existing treatments for hypertension?
How significant are the results of Zilebesiran (ALN-AGT) published in the NEJM in terms of efficacy compared to currently available medications for hypertension?
Added By: catalin_adminIn your opinion, how does Zilebesiran (ALN-AGT) address the unmet medical needs in the treatment of hypertension?
What is the competitive landscape for Zilebesiran (ALN-AGT) in the hypertension market, especially considering the data published in the NEJM?
Based on the NEJM publication, what is the safety profile of Zilebesiran (ALN-AGT), and are there any notable adverse events or side effects?
How might the NEJM publication impact Alnylam's overall pipeline and future development prospects for Zilebesiran (ALN-AGT)?
How does Zilebesiran (ALN-AGT) fit into the broader hypertension treatment landscape, especially in light of the recent results published in the NEJM?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
